A multicenter clinical trial has proved that the Innovative Neurotronics WalkAide is equivalent to the current standard of care, the AFO, for improvements in gait speed and stroke-related quality of life measures. The results indicate that use of the WalkAide produced statistically significant and clinically relevant improvements in several aspects of subjects’ functional mobility and should be considered a viable alternative to conventional bracing for individuals with foot drop caused by chronic stroke. The findings were published February 13 online ahead of print in the journal Neurorehabilitation & Neural Repair.
Hanger, Austin, Texas, the parent company of Innovative Neurotronics, Austin, said it has submitted these findings to the Centers of Medicare and Medicaid Services (CMS) as part of a request for expanded coverage for the WalkAide.
